Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Living Cell Technologies ( (AU:1AI) ) just unveiled an announcement.
Algorae Pharmaceuticals Limited has applied to the ASX for quotation of 47,745 new fully paid ordinary shares under its ticker 1AI, issued on 2 February 2026 following the exercise of options or conversion of other securities. The modest increase in quoted securities slightly expands the company’s free float and capital base, signalling ongoing use of equity-linked instruments in its funding structure but without indicating any immediate transformational change to its operations or market position.
The most recent analyst rating on (AU:1AI) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
More about Living Cell Technologies
Algorae Pharmaceuticals Limited is an Australian-listed biotechnology company in the pharmaceuticals sector, focused on developing therapeutic products. Its shares trade on the ASX under the code 1AI, targeting investors interested in life sciences and drug development opportunities.
YTD Price Performance: 50.0%
Average Trading Volume: 2,479,355
Technical Sentiment Signal: Buy
Current Market Cap: A$35.46M
See more data about 1AI stock on TipRanks’ Stock Analysis page.